Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types for use in human patients. Within a preclinical context, cell types differentiated from iPSCs are tested for their therapeutic response by using animal models. Then, clinical trials are conducted to assure that essential parameters, such as tumorigenicity, dose toxicity, and immunogenicity, are assessed before authorizing the product for use in human patients. [Read more…]
Search Results for: stem cell therapeutic
Steminent Biotherapeutics licenses rights to SCM Lifescience to develop Stemchymal® cell therapy for treating spinocerebellar ataxia (SCA) in South Korea
Taipei, Taiwan, October 13, 2020 — Steminent Biotherapeutics Inc. (President & CEO; Dr. Ling-Mei Wang) and SCM Lifescience Co., Ltd. (KOSDAQ: 298060, hereinafter SCM Lifescience, CEO: BG Rhee) today announced they have signed an exclusive license agreement for clinical development and commercialization of Steminent’s allogeneic cell therapy candidate; Stemchymal® for the treatment of Polyglutamine Spinocerebellar Ataxia (PolyQ SCAs) in South Korea. [Read more…]
TreeFrog Therapeutics and Invetech Expand Partnership to Transition High-throughput Stem Cell Encapsulation Technology to GMP System for Commercial-scale Cell Therapy Manufacturing
-
TreeFrog Therapeutics and Invetech started their collaboration in 2019 to industrialize TreeFrog’s stem cell encapsulation technology to enable the mass production of hPSC-derived cell therapies in industrial bioreactors, with best-in-class cell quality and low production costs.
-
Invetech delivered a beta encapsulation system with a throughput of 1,000 stem cell capsules per second to TreeFrog Therapeutics in the second quarter of 2020.
-
The strategic partnership aims to develop a GMP-compliant encapsulation device by the end of 2022 to support TreeFrog Therapeutics’ in-house and partnered cell therapy programs.
Oscine Therapeutics to Develop Stem Cell Therapies for CNS Disorders with Support from Sana Biotechnology
Oscine Therapeutics is a newcomer to the stem cell sector, a private biotech company exploring mechanisms for treating neurodegenerative disorders through the use of replacing lost or damaged glia cells. The company is based the renowned research of Steve Goldman, M.D., Ph.D., co-director of the University of Rochester Medical Center (URMC) Center for Translational Neuromedicine.
The focus of Dr. Goldman’s research has been to manipulate the chemical signaling of pluripotent stem cell types, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPS cells), to create healthy glia cells. [Read more…]
Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients
– Data show rapid and durable engraftment with MGTA-456, an expanded cord blood stem cell product, in all 18 patients with hematologic malignancies across all conditioning regimens tested –
– MGTA-456 achieves clinical benefits of cord blood transplant –
– Clinically validated process to expand the numbers of CD34+ cells by >300 fold in single cord blood units significantly increases probability of identifying better HLA-matched stem cell donors for patients
December 11, 2017, CAMBRIDGE, Mass.–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 hematopoietic stem cell (HSC) expansion program at the 59th annual meeting of the American Society of Hematology (ASH) in Atlanta, Ga. MGTA-456 is a single umbilical cord blood unit expanded with an aryl hydrocarbon receptor (AHR) antagonist. It is currently being studied in adult and pediatric patients with hematologic malignancies.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 175
- Next Page »